Investigational Therapy BAN2401 Slows Alzheimer’s Progression Over 18 Months, Phase 2 Results Show

Investigational Therapy BAN2401 Slows Alzheimer’s Progression Over 18 Months, Phase 2 Results Show
Treatment with investigational compound BAN2401 over 18 months reduced the accumulation of amyloid fibers in the brain and slowed Alzheimer’s disease progression, according to top-line results from a Phase 2 trial. This follows a previous announcement in December 2017 by Eisai and Biogen, the therapy’s developers, that the treatment had failed to promote significant changes after 12 months. After

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. DANTE MARCIANI says:

    Actually, the efficacy of BAN2401 is based on its capacity to neutralize and facilitate the elimination of the cytotoxic soluble amyloid-beta protofibrils, identified 20 years ago as the oligomeric forms killing neural cells. It is questionable what are the benefits of plaque removal observed at the high dose. Apparently, plaque is solubilized and removed by almost every antibody that binds amyloid, i.e. all of the previous failing antibodies removed plaque. These results support the notion that a well thought vaccine could help in delaying this disease, an approach that as the system ages would need to be replaced by monoclonal therapy in those at risk.

Leave a Comment

Your email address will not be published. Required fields are marked *